Lund LH, Lam CSP, Pizzato PE, Gabrielsen A, et al. Rationale and design of ENDEAVOR: a sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction. Eur J Heart Fail 2023 Jul 20. doi: 10.1002/ejhf.2977.
PMID: 37470101